NewLink Genetics (Ebola vaccine)
M&A
STATUS
Asset Purch.
LATEST DEAL TYPE
1
FINANCING ROUNDS
Description
Portfolio of Ebola vaccine. The vaccine candidate, called rVSV-EBOV, was originally developed by the Public Health Agency of Canada. It is currently being evaluated in phase-I clinical trials.
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Office
- Ames, IA
- United States
NewLink Genetics (Ebola vaccine) Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore NewLink Genetics (Ebola vaccine)‘s full profile, request access.
Request full access to PitchBookNewLink Genetics (Ebola vaccine) Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore NewLink Genetics (Ebola vaccine)‘s full profile, request access.
Request full access to PitchBook